SIRT2 and non-small cell lung carcinoma: Studies have shown that downregulation of SIRT2 decreased the sensitivity to cisplatin treatment in NSCLC, but on the other hand, upregulating SIRT2 by resveratrol treatment sensitized NSCLC cells to cisplatin treatment [124].